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ABSTRACT OF THE DISSERTATION
ASSOCIATIONS BETWEEN ADOLESCENT CANNABIS USE
TRAJECTORIES AND ANXIETY
by
Jacqueline Christine Duperrouzel
Florida International University, 2020
Miami, Florida
Professor Raul Gonzalez, Major Professor
Understanding the effects of cannabis use is critical for reducing adverse behavioral,
social, and academic outcomes, particularly among adolescent users who are most at risk for
cannabis related problems. Although support from both the animal and human literatures
suggests the relationship between cannabis and anxiety may be associated with frequency of
use, much is still unknown. Thus, examining relationships between the most common mental
health issue in adolescence and one of the most commonly used drugs is of great public
health significance and impact. Prior longitudinal studies assessing effects of cannabis use on
anxiety have not evaluated different patterns of use, limiting our ability to identify who may
be most at risk for poorer anxiety outcomes. Assessing the impact of cannabis trajectories on
prospective anxiety will allow us to answer the question of specificity, and the role different
cannabis patterns have on changes in anxiety symptoms and disorders. The current study
leveraged data from a large NIDA-funded study (R01 DA031176) to examine associations
between adolescent cannabis use patterns and changes in anxiety symptomology, disorder
development, and the interactive effects on decision-making, with data collected from 401
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teens across two years. We employed advanced latent growth curve modeling techniques
within an accelerated cohort framework, to allow for additional examination of the effects
patterns of cannabis use have on anxiety during mid to late adolescence. Three cannabis use
trajectories emerged, including a minimal, escalating, and chronic use trajectory. Overall,
findings suggest cannabis use during adolescence is associated with changes in anxiety over
time. Specifically, past week anxiety symptoms increased in escalating and chronic users
relative to minimal users at the two-year follow up. Surprisingly, less cannabis use was
associated with greater likelihood of anxiety disorder development and several hypotheses
are provided as to why this may occur. Further, cannabis trajectory did not influence risky
decision-making independently, but rather interacted with anxiety to influence risk-taking
among minimal users. Overall, the results of the present study were the first to identify how
trajectories of cannabis use influence prospective anxiety in a sample of adolescents across a
two-year time span. Our findings contribute to prevention and intervention efforts by
identifying adolescent users who are most at risk for developing anxiety symptoms and
making poor decisions. Future interventions that target reducing anxiety and cannabis
cessation concurrently will further improve cognitive functioning among heavy users.
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CHAPTER I.
INTRODUCTION TO THE RESEARCH
The program of research that was created for this dissertation examines the effects
of unique patterns of adolescent cannabis use with changes in recent levels of anxiety
(i.e., past week), panic disorder, and general anxiety disorder symptoms and disorder
development. Due to neuromaturational changes occurring in the adolescent
developmental period, it is hypothesized that increasing and high levels of cannabis use
during this time of development affect emotional and cognitive functioning. The current
study first highlights the extant literature on adolescent cannabis use, anxiety, and the
established associations between these two topics. This is followed by preliminary
findings published in the journal Addictive Behaviors to provide rationale for further
exploration of the associations between cannabis use and anxiety. Next, additional
exploration of associations between cannabis use and anxiety are conducted and guided
by my three aims and hypotheses. Aim 1: Examine trajectories of cannabis use among
adolescents and their associations with changes in anxiety symptoms. (1a) Unique
trajectories of adolescent cannabis use trajectories will emerge. Next,trajectories will be
associated with unique increases in anxiety symptoms, such that the minimal-stable group
will be show the lowest increase in anxiety relative to the other trajectories, whereas
escalating users will show the highest increase, and high-stable users will be in-between.
Aim 2: Examine associations between cannabis use trajectories and the development of
an anxiety disorder. (2a) Different use trajectories will be associated with different odds
of developing an anxiety disorder, with users in the escalating trajectory having the
greatest risk of anxiety disorder development. Aim 3: Explore whether anxiety moderates

1

the relationship between cannabis use trajectories and DM. (3a): Anxiety will moderate
associations between cannabis use and decision making, such that for teens with higher
levels of anxiety, heavier patterns of CU (i.e., escalating and chronic trajectories) will be
associated with riskier DM. With lower levels of anxiety, the association between
cannabis use trajectories and DM will be diminished or reversed, such that heavier
patterns of CU (i.e., escalating and chronic trajectories) will be associated with better
(i.e., less risky) DM. Lastly, results of these analyses are provided and discussed in the
context of intervention and prevention efforts.
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CHAPTER II.
Literature Review of Adolescence, Cannabis, and Anxiety
Importance of Examining Adolescent Cannabis Use
Cannabis is among the most widely abused substance by adolescents after alcohol
in the United States, (Johnston et al., 2018), yet many youths do not perceive it as a
harmful substance (Brook, Lee, Brown, Finch, & Brooke, 2011; Hayatbakhsh et al.,
2007). According to the 2016 Monitoring the Future Study (MTFS), the perception of
risk associated with smoking cannabis has continued to decline within the past decade,
with roughly 31% of high-school seniors reporting regular use as harmful, compared to
58% in 2000. Despite low risk perception, consequences of adolescent cannabis use
include difficulties in academic, social, occupational, and mental health domains
(Fergusson & Boden, 2008; Lynskey & Hall, 2000; Volkow, Baler, Compton, & Weiss,
2014;). As of March 2019, 33 states and the District of Columbia have legalized cannabis
for medicinal purposes (NCSL, 2019). Among states with current medical and
recreational cannabis laws, rates of use among youth remain higher when compared to
states without laws not allowing cannabis use (Wadsworth & Hammond, 2018).
Although prior research on the neuroprotective properties of cannabinoids (i.e., antiinflammatory, anti-excitotoxic, antioxidant effects) (Baker, Price, Giovannoni, &
Thompson, 2003; Hampson et al., 2000; Van der Stelt et al., 2001) have informed these
policies, the harmful effects on brain function and associated mental health symptoms of
cannabis on the developing brain are still largely unknown.
It is hypothesized that adolescents may be particularly sensitive to adverse effects
of cannabis because of changes in central nervous system development including
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myelination, synaptic pruning, and structure maturation (Batalla et al., 2013; Lubman,
Cheetham, & Yücel, 2015; Squeglia, Jacobus, & Tapert, 2009). In addition to
adolescence being a critical period of neuromaturation, changes in physical, emotional,
and social functioning are occurring simultaneously (Steinberg, 2005). The rapid changes
occurring across social and biological domains place adolescents at heightened risk for
initiating risky behaviors (Squeglia & Tapert, 2009). There are several relevant and
competing theories as to why adolescents initiate and abuse substances during this
developmental period. Proposed by Bronfenbrenner (1979, 2005), the bioecological
model of development states that as children develop, they interact with four systems: the
microsystem (i.e., individual level factors), mesosystem (i.e., relationship level factors),
exosystem (i.e., community level factors), and macrosystem (i.e., society level factors).
When an adolescent’s personal factors (e.g., rebelliousness) interact with the other three
system factors (e.g., peer pressure (i.e., mesosystem), exposure and access to substances
(i.e., exosystem) and culture/perceived risk (i.e., macrosystem)), it is hypothesized that
substance use occurs (Dodge et al., 2009). Another relevant theory for adolescent
substance use is the dual systems model of cognitive development proposed by Steinberg
and colleagues (2013), which suggests increased risk-taking occurs during this time
because of an imbalance in neural development of certain brain structures, which leads to
heightened reward sensitivity and immature impulse control (Strang, Chein, & Steinberg,
2013). Lastly, a self-medicating hypothesis indicates that substance use may be a
maladaptive coping mechanism for stress and negative emotional states (Khantzian,
1997). Although these theories provide insight into possible factors that influence early
substance use, determining causal mechanisms are still limited. Indeed, emerging studies
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reveal that adolescence is a period of heightened risk taking and the most common period
for initiation of cannabis use (Chen & Kandel, 1995), yet longitudinal examination on
prospective effects is limited. While adolescent patterns of cannabis use are varied,
typical trajectories often include an escalating trajectory in which an individual increases
use over time; a high stable user, in which an individual maintains moderate to high use
over time; and a low stable user, in which an individual maintains low use over time
(Schulenberg et al., 2005). Understanding the effects of how distinct patterns of use may
impact different behavioral and neural processes could have the potential to inform
prevention efforts. Accordingly, focused efforts are needed to investigate the effects of
cannabis use on cognitive, social, and emotional domains to help inform prevention and
intervention practices for the well-being of our youth. Thus, given previously established
associations between cannabis use and mental health problems (Crippa et al., 2009;
Kedzior & Laeber, 2014; Patton et al., 2002), research is needed to elucidate trajectories
that may lead to adverse psychological and cognitive outcomes.
Significance and Effects of Anxiety in Adolescence
Research indicates that anxiety disorders are the most commonly diagnosed
adolescent psychiatric conditions (Conway, Swendsen, Husky, Je, & Merikangas, 2016).
It is estimated that approximately 31.9% of adolescents suffer from at least one of the
five major types of anxiety disorders, which include panic, social anxiety, separation
anxiety, generalized anxiety, and specific phobia disorders (Conway et al., 2016).
Symptoms of anxiety disorders include worry and physiological arousal, such as
restlessness, insomnia, and muscle tension (Beesdo, Knappe, & Pine, 2009). As a result,
anxiety disorders account for decreased productivity, increased morbidity and mortality
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rates, and increased alcohol and drug abuse (King, Iacono, & McGue, 2004).
Furthermore, past findings suggest that the presence of an anxiety disorder in adolescence
increases the risk of secondary psychopathology development, potentially contributing to
educational underachievement and functional impairments (Woodward & Fergusson,
2001). Currently, as detailed by a large body of literature, the most common anxieties in
adolescence are specific phobia and social anxiety disorder (Beesdo et al., 2009;
Merikangas et al., 2010). However, there is a growing literature on the development and
prospective effects of generalized anxiety disorder (GAD) and panic disorder (PD) in
adolescence. According to the Diagnostic and Statistical Manual of Mental disorder, Fifth
Edition (DSM-5), GAD is described as a condition characterized by excessive anxiety
and worries, on most days, for at least six months and causing significant distress in
social, occupational, and other areas of functioning (American Psychiatric Association,
2013). Among adolescents with GAD, alterations in brain connectivity have been
observed in regions of the brain associated with emotional processing (i.e., amygdala,
insula, temporal gyrus, cerebellum, and putamen) when compared to healthy non-anxious
adolescents (Lie et al., 2015). These abnormalities in blood-oxygenated level dependent
(BOLD) signal have been identified during resting state fMRI data acquisition (Lie et al.,
2015), as well as during cognitive task performance (Monk et al., 2008) as demonstrated
by increased BOLD signal within these brain regions. Additionally, findings suggest that
adolescents with severe symptoms of GAD (e.g., high scores modeled by the Pediatric
Anxiety Rating Scale) additionally showed decreased BOLD activation in the prefrontal
cortex when compared to adolescents with mild symptoms (Monk et al., 2008).
Similarly, patterns of decreased BOLD levels have been observed in the medial
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prefrontal cortex in patients with PD when compared to healthy matched controls (Zhao
et al., 2007). Described by the American Psychiatric Association (2013), PD is
characterized by recurrent panic attacks, with one or more attacks followed by at least a
month of fear related to panic attacks. The implications of GAD and PD symptomology
on BOLD within the prefrontal cortex may be translational and observed in decisionmaking (DM) and higher order executive functioning, thus impacting an adolescent’s
overall cognitive abilities.
Comparable to the documented cannabis use trajectories, developmental patterns
of anxiety have been studied. Prior research indicates that anxiety follows a natural
waxing and waning profile across adolescence (Kessler, Ruscio, Shear, Wittchen, 2009).
Yet, disparities between anxiety disorder growth and reduction rates have revealed
differences between PD and GAD, such that PD symptoms decrease in early to middle
adolescence compared to increases in GAD symptomology (Hale III, Raaijmakers,
Muris, & Meeus, 2008) during the same time period. Furthermore, although anxiety
disorders are common among teens, many individuals do not seek treatment (Coles &
Coleman, 2010), despite established effective therapeutic strategies (Walkup et al., 2008).
Rather, individuals with earlier onset (Douglas et al., 2010) and untreated anxiety are at
greater risk for mood difficulties and substance use (Brown, Campbell, Lehman,
Grisham, & Mancill, 2001). Such findings highlight the need to better understand and
address the unique mechanisms that contribute to the development of distinct anxiety
disorders among youths, as well as, what propagates maladaptive coping mechanisms,
such as substance abuse, among youth.
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Associations between Cannabis Use, Anxiety, and the Brain
A biopsychosocial conceptualization of how anxiety and cannabis use may be
related include evaluating physiological arousal, cognitive thoughts, and feelings within
the context of an individual’s life (See Figure 1). Although it is proposed that biological,
social, and psychological factors interact to influence the relationship between anxiety
and cannabis, we suggest that the association is influenced by a negative reinforcement
model of anxiety (See Figure 2). Our proposed reinforcement model for using cannabis
may be attributed to an individual’s attempt to regulate negative emotional and
physiological states in the short term (Buckner, Heimberg, Ecker, & Vinci, 2013), rather
than regulating stress and worries via evidence-based methods (e.g., cognitive
restructuring and relaxation techniques). Additionally, utilizing cannabis as a coping
mechanism for anxiety may be influenced by social pressures (Buckner, Bonne-Miller,
Zvolensky, & Schmidt, 2007), genetic underpinnings (Merikangas & Avenevoli, 2000),
and psychological traits (Kotov, Gamez, Schmidt, & Watson, 2010).
Another viable factor for the maintenance of comorbid cannabis use and anxiety
within the biopsychosocial framework is comparable neural activations within emotional
processing regions of the brain (Lantela, Kamal, & Kamal, 2018). Cannabis exerts its
effects on the central nervous system (CNS) through the binding of its primary
psychoactive constituent delta-9-tetrahydrocannabinol (THC) to cannabinoid 1 (CB1)
receptors distributed throughout the brain (Iversen, 2003). There is significant overlap
between brain structures with large densities of CB1 receptors and those implicated with
processes of anxiety, thus providing a viable mechanism through which cannabis use may
impact anxiety symptomology. Specifically, the amygdala and prefrontal cortex—brain
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regions recruited in anxiety and executive functioning processes which include planning
and DM (Blakemore & Robbins, 2012; Ochsner & Gross, 2005)—are known to have a
high density of CB1 receptors (Iversen, 2003; Ochsner & Gross, 2005; Rey, Purrio,
Viveros, & Lutz, 2012). Although cannabis use may reduce subjective anxiety acutely,
the picture is more complex. Cannabis is known to have a dose-biphasic effect with high
levels of THC resulting in symptoms of acute anxiety and low levels resulting in an
anxyioltic effect (Rey et al., 2012). Research conducted in rodents shows that chronic
exposure to cannabis during adolescence can influence neural microstructure by reducing
CB1 receptor levels in cortical brain regions (Hirvonen et al., 2012; O’shea, Singh,
McGregor, & Mallet, 2004; Rubino et al., 2007). The downregulation of receptors is
hypothesized to exacerbate anxiety, as normal endocannabinoid signaling is disrupted
(Katona et al., 2001; Martin, Ledent, Parmentier, Maldonado, & Valverde, 2002).
Discovered in 1990s, the endocannabinoid system can be found in the central and
peripheral nervous systems and aids in several physiological and cognitive processes
including motivation, control, and reward, (Maldonado, Valverde, & Berrendero, 2006).
Mirrored in human literature, an adult study utilizing positron emission tomography
(PET) revealed a 20% reduction of CB1 receptors across the brain in heavy users when
compared to those with limited levels of cannabis exposure across their life (Hirvonen et
al., 2012). The anatomical disruption of CB1 receptor density, in conjunction with
exogenous cannabinoid consumption could potentially influence neurotransmitter,
chemical, and hormonal signaling, thereby contributing to the development of
psychological and mood disorders (Ashton & Moore, 2011). These effects observed after
long-term use suggest that regular cannabis use may impact neurobiological processes
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relevant to anxiety (Braida, Limonta, Malabarba, Zani, & Sala, 2007; Muntoni et al.,
2006; Viveros, Marco, & File, 2005) and influence neuropsychological functioning
including DM (Crean, Crane, & Mason, 2011). Although downregulation of CB1
receptors with chronic use may be reversible upon cessation of use (Hirvonen et al.,
2012), it is not clear whether that is the case when use occurs during adolescence.
Moreover, disruptions in receptor densities during a period marked by heightened neural
development may make adolescents more susceptible to long-lasting receptor disruptions
(Lubman et al., 2015; Schneider, 2008) and more severe consequences of cannabis use.
Recently, there has been accumulating evidence suggesting heavy cannabis use
during adolescence is associated with social anxiety disorder (SAD), the most commonly
studied anxiety disorder among adolescent cannabis-using samples (Buckner, Schmidt,
Bobadilla, & Taylor, 2006; Buckner et al., 2007; Buckner et al., 2008; Buckner,
Heimberg, Mathews, & Silgado, 2012; Buckner et al., 2012). Despite insights on the
association between cannabis use and SAD, little is known on how various patterns of
use affect other anxiety symptomology over time, specifically with regards to PD and
GAD. Historically, cannabis use has been associated with symptoms of panic (Tunving,
1985). These findings have influenced a relatively small line of research that explores the
dose-dependent effects of cannabis on physiological symptoms of anxiety. Findings from
these studies have provided support for the association of heavier use with acute panic
attacks (Crippa et al., 2009; Szuster, Pontius, & Campos, 1988) and future development
of PD (Zvolensky, Lewinsohn, Bernstein, Schmidt, & Buckner, 2008). Accordingly,
research examining GAD with cannabis use is scarce. Of interest, one longitudinal study
found that any cannabis (i.e., >1x time) use is associated with increased PD and GAD
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development compared to individuals who do not use cannabis (Van Laar, Van
Dorsselaer, Monshouwer, & De Graaf, 2007).
Additionally, chronic cannabis use in adolescence has been associated with
cognitive impairment (Meier et al., 2012), but examination of the interactive effects of
adolescent cannabis use and anxiety on domains of cognitive functioning has not
occurred. Furthermore, longitudinal studies evaluating associations among cannabis use
trajectories and changes in anxiety symptoms and anxiety disorder development are
scarce. More information regarding the factors that contribute to associations between
anxiety and cannabis use warrants additional exploration.
Preliminary data from our lab published in the journal Addictive Behaviors,
identified that early levels of cannabis use influence rates of change in self-reported past
week anxiety symptoms in a sample of 250 adolescents across a one-year period
(Duperrouzel et al., 2018). Data on participants’ past month cannabis frequency and past
week’s subjective anxiety symptoms informed this relationship. Our prior work suggests
greater levels of cannabis use are associated with a slower decrease in anxiety symptoms
over time (relative to the sample average) in adolescents, even after accounting for
concurrent depression, alcohol, and nicotine use (β = 15, p <.05). In addition, our results
highlight differences between varying levels of cannabis use and anxiety symptoms,
lending support to theoretical models that support the theory that early onset substance
use impacts mental health (Wittchen et al., 2007). However, whether the maintenance of
this association persists across larger samples and time-frames, as well as whether this
association generalizes to other anxiety disorder symptoms remain unknown. Given these
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gaps in our understanding of adolescent cannabis use and anxiety, it is timely to examine
these associations.
Summary and Proposed Study
Although relationships between psychopathology and cannabis use is being
ardently studied, especially with regards to psychosis and schizophrenia (Brook et al.,
2011; Hall & Degenhardt, 2000; Hayatbakhsh et al., 2007), associations with nonpsychotic disorders have received far less attention. An area receiving increasing
attention is the association between cannabis use and anxiety. Understanding the effects
of cannabis use is critical for reducing adverse behavioral, social, and academic
outcomes, particularly among adolescent users who are most at risk for cannabis related
problems. Although support from both the animal and human literature suggests the
relationship between cannabis and anxiety may be influenced by levels of use, much is
still unknown. Thus, examining relationships between the most common mental health
issue in adolescence and one of the most commonly used drugs is of great public health
significance and impact. Prior longitudinal studies assessing effects of cannabis use on
anxiety have not extensively evaluated different patterns of use, limiting our ability to
identify who may be most at risk for poorer anxiety outcomes. The need to assess
cannabis trajectories with changes in anxiety over time will allow us to answer the
question of specificity (i.e., who is more adversely affected) and the role that different
cannabis patterns have on prospective anxiety symptom and disorder development.
Findings from this research are expected to advance our understanding of the association
between cannabis use and anxiety. Thus, the aims of this dissertation are: Aim 1:
Examine trajectories of cannabis use among adolescents and their associations with
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changes in anxiety symptoms. (1a) Previously identified trajectories will be associated
with unique increases in anxiety symptoms, such that the minimal-stable group will be
show the lowest increase in anxiety relative to the other trajectories, whereas escalating
users will show the highest increase, and high-stable users will be in-between. Aim 2.
Examine associations between cannabis use trajectories and the development of an
anxiety disorder. (2) Different use trajectories will be associated with different odds of
developing an anxiety disorder, with users in the escalating trajectory having the greatest
risk of anxiety disorder development. Aim 3: Explore whether anxiety moderates the
relationship between cannabis use trajectories and DM. (3): Anxiety will moderate
associations between cannabis use and decision making, such that for teens with higher
levels of anxiety, heavier patterns of CU (i.e., escalating and chronic trajectories) will be
associated with riskier DM. With lower levels of anxiety, the association between
cannabis use trajectories and DM will be diminished or reversed, such that heavier
patterns of CU (i.e., escalating and chronic trajectories) will be associated with better
(i.e., less risky) DM..
CHAPTER III.
METHODOLOGY
Subjects and Setting
My study leveraged data from a NIDA funded project (R01DA031176 PI:
Gonzalez) examining the neurocognitive effects of adolescent cannabis use. Participants
are 401 adolescents at risk for cannabis use escalation from the greater Miami area. They
were recruited via in-person recruitment efforts at Miami-Dade County public middle and
high schools, flyers distributed throughout South Florida, and word-of-mouth. Adolescent
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eligibility was ascertained via phone screen, and parental verbal and written consent were
obtained prior to assessment scheduling. Participants in the study were all between the
ages of 14-17 at the time of their baseline evaluation and were able to read and write in
English. By design, most had previous exposure to either alcohol, cigarettes, or other
drugs (even if only minimal), Participation exclusionary criteria included self-reported 1)
developmental disorders (e.g., delays in motor and language abilities), 2) neurological
conditions (e.g., stroke, brain aneurism, seizures, epilepsy), 3) birth complications (e.g.,
born <37 week-gestation) , 4) history of self-reported diagnosis of mood disorder or
thought disorder at screening, 5) traumatic brain injury or loss of consciousness > 10
minutes, 6) history of significant alcohol use or substance use suggestive of an alcohol
use disorder (AUD) or cannabis use disorder (CUD), 7) use of other drugs (besides
alcohol, cannabis, and nicotine) more than 10 times, 8) use of any other drugs in the two
weeks prior to assessment, and 9) use of any other drug to an extent greater than their
cannabis use. Participants completed a detailed baseline assessment by trained examiners
that included measures of substance use, executive functioning, risky behaviors, and
mood. Five measurement waves of data were conducted bi-annually for two years. The
baseline and 1-year follow-up assessments (T3 and T5) queried all aforementioned areas,
as well as, oral toxicology and breath tests for assessment of trace levels of recent drug
use. All one-year follow up assessments were conducted at a laboratory during a visit
lasting approximately 4 hours. The 6-month follow-up assessments (T2 and T4) were
conducted through a telephone call lasting approximately one hour and focused on past 6month substance use and mood symptoms. Data collected for aims 1 and 2 utilized
measures administered at all five assessment waves, whereas the aim 3 DM data
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examined all in-person assessments (i.e., 3 waves of data), see Figure 3. Participant
characteristics for the sample are presented in Tables 1-4. The Institutional Review Board
of Florida International University (FIU) approved all study procedures and protocols
(IRB-13-0065-AM37).
Measures
Self-report measures, structured and semi-structured interviews, and computer based
decision-making tasks were utilized to assess substance use, mood, and DM. All data was
uploaded to a secure encrypted online platform (REDCap).
Demographic Information. Information regarding participant’s age, race,
ethnicity, gender, years of education, parental education, birth, medical, and substance
use history were collected via the clinician-administered Personal History Questionnaire
(PHQ) at each assessment wave.
Toxicology Testing. All participants underwent breath alcohol and carbon
monoxide (CO) testing at baseline, T3, and T5 (BACtrack S80; piCO+ Smokerlyzer –
coVita). The alcohol breath test assessed for alcohol concentrations between 0.00-.500%
within 3 seconds. Whereas, the CO testing detected for levels of 0-150 ppm CO in <30
seconds. Additionally, participants underwent oral fluid toxicology testing for recent
drug use of THC, cocaine, opiates, and amphetamines using the Intercept oral fluid drug
test at all in-person assessments (OraSure Technologies, Inc.: Bethlehem, PA; Langel et
al., 2008).
Substance Use. Detailed substance use history was obtained using the Drug Use
History Questionnaire (DUHQ) (Duperrouzel et al., 2019; Rippeth et al., 2004), a semistructured interview assessing self-reported frequency and quantity of substance use
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across 15 different classes of substances during a participant’s lifetime, past six months,
and past 30 days. In addition to cannabis use, data were obtained on alcohol, nicotine,
cocaine, amphetamines, methamphetamine, ecstasy, heroin, opiates, benzodiazepines,
barbiturates, club drugs, hallucinogens, PCP, and inhalants. Cannabis use frequency (i.e.,
number of days used) from the past six months will be our primary measure for
generating cannabis use trajectories for our analyses.
Anxiety Symptoms Measures. Anxiety symptoms were assessed through a selfreport questionnaire and a semi-structured interview.
Past week symptoms of anxiety were assessed using the short version of the
Depression, Anxiety, Stress Scale (DASS-21; Henry & Crawford, 2005), a 21-item selfreport questionnaire used to assess symptoms of depression, anxiety, and stress during the
past week. Items are rated on a 4-point scale, ranging from 0 (“Did not apply to me at
all”) to 3 (“Applied to me very much, or most of the time”). Evidence of reliability and
validity of the DASS-21 (α = 0.81; 95% CI: 0.79–0.84) among adolescents has been well
established (Szabó, 2010). Seven statements assessing anxiety included awareness of
dryness of mouth, breathing problems, action of heart, trembling, feeling worried, feeling
close to panic, and feeling scared. The current study used this measure's 7-item anxiety
subscale standardized z-scores as an outcome measure of anxiety. Stress and depression
subscale z-scores were controlled for in follow-up analyses and used as covariates for
Aims 1-3.
The Computerized Diagnostic Interview Schedule for Children (C-DISC), a
structured reliable interview for children and adolescents (Shaffer, Fisher, Lucas, Dulcan,
& Schwan-Stone, 2000), was used to identify the following disorders: panic disorder,
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general anxiety disorder, obsessive compulsive disorder, major depression disorder,
mania/hypomania, attention deficit/hyperactivity disorder, oppositional defiant disorder,
and conduct disorder at all in-person assessment waves (i.e., baseline, 1-year follow-up
(T3), and 2-year follow-up (T5)). The C-DISC also provides number of symptoms
endorsed with each disorder, impairment level, and sub-clinical intermediate diagnoses.
PD and GAD symptoms and disorder diagnosis were used as anxiety outcome variables
for Aims 1 and 2.
Decision-Making.
At all in-person visits (baseline, T3, and T5) decision-making (DM) was
examined with three computerized tasks assessing DM under various conditions of risk
and reward. Structural equation modeling was employed to generate a latent construct of
DM performance at T5 with data from each of the DM tasks (Pacheco-Colón, Hawes,
Duperrouzel, Lopez-Quintero & Gonzalez, 2019).
The Iowa Gambling Task (IGT) was used to assess DM under ambiguous risk
(Bechara, Damasio, Damasio, & Anderson, 1994). Participants completed 100 trials in
which they had to select from four card decks, which included two “good” (i.e., Decks C
and D) and two “bad” (i.e., Decks A and B) decks, in an attempt to yield a positive net
total of monetary earnings. Participants were told that when they select a card, they will
win money, sometimes lose money, and that some decks are better than others. To obtain
a positive net total at game completion, a participant would had to have made more
selections from “good” rather than “bad” decks. The Net Score was derived from the
selection of bad decks subtracted from the selection of good decks and was used as an
indicator for the DM latent variable. As recommended in the IGT Professional Manual,
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we reverse scored the Net Score to aid with interpretation of findings (Bechara, 2007) in
our analyses. Prior research utilizing the IGT with individuals that use cannabis found
that poor DM moderated relationships, between cannabis use and risky behaviors; such
that at high levels of cannabis use better DM was associated with less risky behaviors,
whereas poorer DM was associated with increased risk-taking (Ross, Coxe, Schuster,
Rojas & Gonzalez, 2015).
Additionally, the Game of Dice Task (GDT) was used to assess DM under
explicit risk probabilities (Brand et al., 2005). Participants made selections for simulated
monetary gain by evaluating the probability of winning or losing across 18 trials. During
the GDT, combinations of one to four dice are presented and participants were instructed
to pick one of the combinations presented on each trial. Probabilities of earning a specific
outcome are associated with the number of dice selected, with high risk choices (i.e., 1 or
2 dice options). associated with higher gains but greater probabilities for large losses.
Alternatively, low risk choices are associated with higher probabilities of winning smaller
gains (i.e., 3 or 4 dice options), but with the risk of smaller possible losses. Total number
of risky trials was used as an indicator for the DM latent variable.
Lastly, the Cups Tasks (CT) was used to assess DM under conditions of specified
risk separately for conditions of gain and loss (Levin & Hart, 2003; Levin, Hart, Weller,
& Harshman, 2007). Participants were instructed to pick a cup from one of two sides that
would either yield a definite reward/smaller loss, or from the opposite side that provided
a chance for a greater reward/loss. Each participant completed 54 trials of potential
“gain” or “loss” and had their total earnings summed upon completion. The number of
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risky choices in the gain domain and number of risky choices in the loss domain were
used as indicators for the DM latent variable.
Statistical Analyses
All analyses were conducted in either SPSS v.23. or MPlus v.8.2 (Muthen &
Muthen, 2000-2012). Analyses consisted of examining associations between cannabis use
trajectories and anxiety, as well as, the moderating role of anxiety on the relationship
between cannabis pattern (i.e., class trajectory) and decision-making performance at T5.
Participant Characteristics.
Demographics and sample data characteristics were evaluated for normality,
skew, kurtosis, and outliers. Additionaly, baseline characteristics revealed group
differences for age, sex, race, and amount of cannabis use.
Data Analysis Plan for Aim 1.
Cannabis use trajectories were estimated to identify unique cannabis use patterns
within our sample. Lifetime cannabis frequency was phase to age converted and modeled
within an accelerated cohort design. One advantage of utilizing this modeling framework
is that it allows for estimation of a trajectory over a longer time-frame than would have
been otherwise possible than if it modeled as assessment timepoints (Galbraith, Bowden,
& Mander, 2017). Additionally, this method accounts for planned missingness associated
with participant drop-out and missed assessment visits (Galbraith et al., 2017), both of
which are common in longitudinal studies. To determine a participant’s cannabis use
trajectory membership, probabilities were generated and used to develop a model for
latent class growth analysis (LCGA) in Mplus using maximum likelihood estimates. A
series of models were tested to determine if cannabis growth patterns were best estimated
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as either linear or quadratic (i.e., slopes) growth factors. To determine the most optimal
number of classes we selected a model based on theoretical interpretation, parsimony,
and fit indices.
After selecting the best fitting model, we implemented maximum probability
assignment (MPA) (i.e., hard classification) to identify latent classes of cannabis use
trajectories in Mplus. Our decision to use MPA over the statistically novel “three-step
approach” for modeling auxiliary variables (Asparouhov & Muthen, 2014) was guided by
findings from our initial trajectory model. When using the three-step procedure, cannabis
use trajectory estimates are calculated without a distal outcome (dependent variable)
included in the model, whereas MPA includes all outcome variables within the initial
model. The three-step procedure statistically accounts for classification uncertainty in an
individuals’ trajectory group assignment by using class membership probabilities, which
leads to reduced bias in model parameter estimates and standard errors when contrasted
with other commonly used approaches (e.g., MPA). However, this approach is only
particularly helpful when there is a large uncertainty for classifying participants. In other
words, the three-step approach is superior when classification certainty is poor (entropy =
< .60). However, when class accuracy is high, the MPA approach has comparable
efficiency (Asparouhov & Muthen, 2014). Because entropy (i.e., predictability in class
accuracy) was high within our initial model (entropy = .93), we decided against the threestep approach. Furthermore, the three-step approach is a more complex statistical model
that makes it more difficult to incorporate other parts compared to MPA. Next, the
subsequent sets of analyses examined (1) cannabis use trajectory group membership as a
predictor of changes in anxiety symptomology across the duration of the study (2 years).
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When examined as a distal outcome variable, DASS-21 scores were treated as
having unequal means and variances across the cannabis use trajectory groups. These
analyses accounted for covariate effects (e.g., participant demographics, depression,
baseline alcohol and nicotine use). Additionally, residualized change scores were
calculated for DASS-21 symptoms from baseline to T5 to examine change in anxiety
across a two-year time-frame. We used a residualized change approach to examine
change in anxiety symptomology because it takes into account baseline anxiety levels and
additional predictors of interest when examining change over time. That is, within the
regression model, anxiety at T5 is regressed on itself at baseline with covariates. Thus,
the outcome (residualized) scores represent only variability that is unexplained by
baseline levels and is interpreted as change over the study period (Castro-Schilo &
Grimm, 2018). We subsequently followed the same prescribed procedure, to examine the
associations between changes in panic disorder and generalized anxiety disorder
symptomology from baseline to T5, utilizing data from the C-DISC with cannabis use
trajectory membership (see Figures 6-8).
Data Analysis Plan for Aim 2.
Logistic regressions were conducted to examine differences in the odds of anxiety
disorder development between cannabis trajectory groups. Odds ratios provide relative
odds of a participant belonging to a cannabis trajectory, per 1-unit increase in disorder
outcome. That is, is the development of an anxiety disorder throughout the study period
associated with distinct cannabis use trajectories? We ran separate logistic regression
models for GAD and PD, using presence of past year disorder as captured by the CDISC, at T3 and T5 assessments. The CDISC predictor variables were binary with “0”
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indicating not having the disorder, and “1” having the disorder. In all analyses we
controlled for sex, and comorbid lifetime alcohol and nicotine frequency. Follow-up
analyses explored controlling for depression and exploring sex effects.
Data Analysis Plan for Aim 3.
First, we identified theoretically relevant covariates that may influence
associations between cannabis use and neurocognitive functioning, which included sex,
age, estimated IQ, as well as alcohol and nicotine frequency at T5. Next, we generated
the DM latent variable, which consisted of the reverse scored Net Total on the Iowa
Gambling Task, total number of risky choices on the Game of Dice, and total of risky
choices in gain domain and total risky choices in loss domain on the Cups Task at T5,
with all indices loading significantly onto the latent factor (ps <.05). We then examined
associations between DM T5 performance and cannabis use trajectories, as well as, pastweek anxiety symptoms utilizing the DASS-21 anxiety sub-scale as a moderator for the
aforementioned association. To do this, we first ran separate linear regressions model to
examine univariate associations between cannabis use trajectory and DM, and between
anxiety and DM. Next, to explore the potential moderating influence of anxiety, we then
ran a multiple regression which included anxiety, cannabis trajectory, and their
interaction. To further explore significant interactions, we conducted separate linear
regressions examining the effects various levels of anxiety had on associations between
cannabis use trajectories and DM.
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Missing Data Analyses.
The proportion of participants with complete data at their baseline evaluation was
401 (100%). Cannabis use data collected at the follow-up T2 assessment was available
for 391 (98%) participants, followed by data from 383 adolescents (96%) for the T3
assessment, 380 adolescents (95%) at T4, and 387 (97%) participants at T5. Patterns of
missingness were assessed, and we found no evidence that our data was not missing at
random (MAR), with no variable differences found for participants with complete versus
incomplete datasets. Full-information maximum likelihood (FIML) methodology was
applied to all analyses, as the FIML procedure uses all available data points to construct
parameter estimates without imputing individual values (Enders & Bandalos, 2001). All
401 subjects had at least one data point and were therefore used to inform the maximum
likelihood estimates.
CHAPTER IV.
RESULTS
Descriptive Statistics.
Participants were predominantly high school students of Hispanic ethnicity and
White race, with roughly equal representation of males and females. It is to be noted,
substance use variables were skewed, as is typical of studies with substance using
samples. Although participants reported a varied range of alcohol, nicotine, and cannabis
use, use of cannabis generally exceeded use of alcohol and nicotine. At baseline, nine
participants met criteria for current cannabis use dependence and no participants met
criteria for dependence for any other substance. Median lifetime days of cannabis use at
T1 for the whole sample were 21, with interquartile range from one to 145 days.
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Furthermore, few participants met diagnostic criteria for an anxiety disorder at baseline
(n=17; ~4%). Detailed information for primary study variables is presented in Tables 1-4
by cannabis use trajectory.
Aim 1 Result Part A: LCGA of Cannabis Use Trajectories.
Initial examination of the unconditional growth model of cannabis use showed
acceptable model fit (χ2[25] = 139.95, p < .001; CFI = .91; RMSEA = .10). The mean
estimated intercept (x̅ = .33, SE = 0.07) and linear slope (x̅ = 0.57; SE = 0.08) were
significant and positive (p’s <.001). Importantly, statistically significant variance
estimates were found for the intercept (p < .001) and linear slope (p < .001), indicating
significant between-individual variability in initial levels and change over time in
cannabis use; that is on average, people increased cannabis use with age but varied in
how their use changed over time.
Next a series of LCGA models were conducted to determine the number of latent
classes in our sample that would allow us to examine associations between anxiety and
different patterns of cannabis use among adolescents.
Following examination of the single-class model, LCGA was used to examine
trajectories of cannabis use, controlling for study covariates (e.g., participant
demographics, co-occurring alcohol and nicotine use). These analyses were explored in a
step-wise fashion, beginning with a two-class solution and ending with a four-class
solution. Based on substantive interpretation, parsimony, and fit indices, a three-class
model of adolescent cannabis use was identified as providing the best overall solution
(see Table 5). Although a four-class model was also considered (see Figure 5), two of
these four trajectory groups, both of which were relatively small (n’s < 35; < 10% of total
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401), followed similar escalating patterns of use, which appeared to be largely captured
by the more parsimonious, three-class solution. For the three-class model (see Figure 4),
the total sample size for each of the classes exceeded 10% of the total sample, and the
trajectories were similar to those observed in prior research (Flory, Lynam, Milich,
Leukefeld, & Clayton, 2004). The three classes were labeled based on frequency of use
with the following categories: minimal use (i.e., consistently low levels throughout
adolescence), chronic use (i.e., consistently elevated levels throughout adolescence), and
escalating use (i.e., significantly accelerating use throughout adolescence). The first
class, with 262 participants (65%), displayed consistently low levels of cannabis use
across the study period (“minimal”). For the minimal class, mean estimated intercept (x̅ =
3.12, SE = 1.28) and linear slope (x̅ = 1.31; SE = 0.39) were significant in the positive
direction (p’s <.001). The second class included 61 participants (15%) with chronically
high levels of cannabis use, which were characterized by high initial levels of use that
remained persistent across assessments (“chronic”). For the chronic class, mean estimated
intercept (x̅ = 75.97, SE = 14.48) and linear slope (x̅ =11.76; SE = 2.97) were significant
in the positive direction (p’s <.001). Lastly, the third class included 78 participants (20%)
that displayed initially low levels of cannabis use and escalated their use across the study
period (“escalating”). For the escalating class, mean estimated intercept (x̅ = -2.07, SE =
7.04) and linear slope (x̅ = 15.30; SE = 2.04) were significant in the positive direction (p’s
<.001). Additional baseline statistics by cannabis trajectory group are presented in Table
1.
Covariates retained in the analysis included sex, ethnicity, and baseline alcohol
and nicotine use. The addition of covariates in the LCGA model did not alter fit statistics,
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cannabis use pattern profiles, or the size of observed classes. Fit information for each
model considered can be found in Table 5 and trajectory plots of the three and four class
models can be found in Figures 4 and 5.
Aim 1 Results Part B: Cannabis Trajectories and Change in Anxiety.
Multiple regression models were conducted in Mplus to examine associations
between cannabis use trajectory class membership and changes in anxiety symptomology
from baseline to two-year follow-up. To identify differential effects of certain anxiety
symptoms, models were conducted separately with changes in anxiety symptoms (i.e., in
the past week) as measured by the DASS-21, as well as for changes in GAD and PD
symptoms as measured by the C-DISC. All models accounted for sex, ethnicity, and
comorbid alcohol and nicotine use. The model examining DASS-21 symptoms, found a
significant effect of cannabis use trajectory on residualized change in past week anxiety
symptoms (β = .11, p=.002). To explore between group comparisons, we used the
grouping command in Mplus. Results from this model revealed a significant betweenclass difference in change in anxiety over time, specifically between the escalating and
minimal trajectories (β = -0.322, p <.01); see Figure 6. These findings indicate that
participants in the escalating trajectory had larger gains in past week anxiety symptoms
across the study compared to the other trajectories. Additionally, associations between
sex and changes in past week anxiety symptoms were found across all cannabis use
trajectories (ps <.001). We conducted follow-up analyses to explore potential sex
differences and created a sex by change in anxiety interaction term and included this term
as a predictor in our subsequent models. These follow up analyses revealed that there was
a significant interactive effect for change in anxiety and sex on group trajectory (β = .28,
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p= .024). Further these results revealed that females across all trajectories had greater
change (i.e., decreases) in anxiety when compared to males from T1 to T5. Furthermore,
the association between cannabis use trajectory membership and change in anxiety
among females was significant for both the escalating and chronic trajectories relative to
minimal users (ps<.05), suggesting that frequent and increasing cannabis use impacts
anxiety more among adolescent females when compared to males. However, the main
finding of sex diminished for males (ps >.05), indicating change in anxiety does not vary
for males across trajectory groups. Thus, it appears that being female accounts for all sex
differences in anxiety change and cannabis use group.
The same prescribed procedure above was conducted with change scores in GAD
and PD symptoms; however, no significant associations were found between cannabis
group membership and change in these symptoms and (ps> .05); see Table 6 and Figures
7 and 8.
Aim 2 Results: Odds of Developing an Anxiety Disorder at T3 or T5.
To determine if cannabis use trajectory predicted anxiety disorder development, logistic
regressions were conducted with group-wise comparisons (i.e., chronic vs. minimal;
chronic vs. escalating; minimal vs. escalating) are provided in Table 7.
Development of PD at T3:
After accounting for sex (p<.001), alcohol (p=.009), and nicotine (p= .002) use,
there was no effect of cannabis use trajectory group on the odds of developing PD by the
one-year follow-up assessment (i.e., T3); (β = .877, p>.05); see Figure 7. Odds ratios for
group wise comparisons, revealed minimal users were more at risk of developing PD
(p<.05). No other group comparisons were significant (p > .05). However, due to the

27

observed association of sex with PD symptoms, we conducted follow-up testing with a
sex by cannabis group interaction term which revealed a significant interaction for sex
and cannabis use group on development of PD at T3 (β = .773, p <.001). To further
explore sex differences, we conducted our initial model separately for males and females,
and a significant association was found between cannabis use class and PD development
for females (p =.002), but not males (p =.610). Such that females across all cannabis
trajectories had greater likelihood of developing PD than males.
Development of PD at T5:
After accounting for sex (p<.001), alcohol (p =.005), and nicotine (p = .001) use,
cannabis use trajectory class membership did not predict the odds of developing PD by
the two-year follow-up assessment (T5; p >.05). Nor, did the group comparisons between
minimal and escalating trajectories reveal significant differences in PD development (p
>.05). Additionally, odds ratio comparisons between groups with the chronic cannabis
use trajectory could not be conducted because no members within this group developed
PD at T5. However, due to the observed association of sex with PD symptoms, we once
again conducted follow up testing with an interaction term of sex by cannabis group.
Within these analyses, after accounting for the previously mentioned covariates, there
was a significant interaction effect for sex by cannabis group (β = .713, p < .001). To
explore sex differences between groups, we ran our initial model separately for males and
females, and a significant association was found on development of PD at T5 for males (β
= -.915, p <.001). This effect indicated that males in the escalating trajectory had
significantly higher odds of developing PD than males in other groups.
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Development of GAD at T3:
After accounting for sex (p<.001), alcohol (p =.004), and nicotine (p = .001) use,
an association was found between cannabis use trajectory class membership and GAD
development by the one- year follow up assessment (T3; p =.05), see Figure 8. Follow up
analyses revealed a significant difference in development of GAD development between
the minimal trajectory and the escalating trajectory (β = .667, p <.001), such that
participants in the minimal group had significantly greater odds of developing GAD than
those participants who were increasing their cannabis use across a one-year period. There
was also a significant difference in developing GAD between the chronic and escalating
trajectories at the one-year follow-up (β = - .499, p <.001). However, odds ratio values
for group comparison could not be computed with participants from the chronic trajectory
because no members developed GAD. Yet, these findings indicate that adolescents with
consistently high levels of use had less risk of developing GAD than those exposed to
minimal or increased use.
Additionally, because there is accumulating evidence to suggest that internalizing
disorders develop more in females and males, we wanted to explore potential sex effects
among our cannabis use trajectories. Since sex was significantly related to cannabis use
trajectory and GAD development in our sample, we conducted follow up analyses with a
sex by cannabis group interaction term to explore potential sex effects. Within these
follow up analyses, after accounting for the previously mentioned covariates, a
significant association was found for cannabis use class membership and sex on GAD
development for females (p <.001) when compared to males (p =.610). To identify sex
differences between classes, further analyses were employed. The results of these

29

analyses revealed females within the minimal trajectories were more likely to develop
GAD when compared to males in this group (p<.05).
Development of GAD at T5:
After accounting for sex (p <.001), ethnicity (p =.022), alcohol (p =.005), and
nicotine (p= .001) use, no association was found between cannabis use trajectory class
membership and GAD development at the two-year follow up assessment (T5; p >.05).
Comparable to GAD T3 results, odds ratio values for group comparison could not be
computed with participants from the chronic trajectory because no members developed
GAD. However, due to the significant independent effects of sex and cannabis group on
this association at T3, we also employed these same follow up models to explore
interactive effects of sex and cannabis group on T5 GAD developments. Within these
follow-up analyses, after accounting for the previously mentioned covariates, a
significant association was found for cannabis use class membership and GAD
development for females (p = .004) and trending towards significance for males (p =.053)
at two-year follow up. Further exploration of sex differences revealed, a greater GAD
development among female users in the escalating trajectory (β = -.830, p =.004) when
compared to those in the chronic and minimal trajectories. These results indicate that
females in the escalating trajectory had greater risk of developing GAD than females with
other patterns of cannabis use.
Accounting for Depression with PD & GAD Development:
As a result of frequent comorbidity of depression and anxiety pathology, all
analyses were repeated accounting for depression at baseline and two-year follow up.
Due to relatively minimal clinical levels of anxiety within our sample, we refrained from
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including depression in our initial models because of potentially over-accounting for
variance captured by comorbid internalizing disorders. Nevertheless, across all follow-up
analyses all main findings remained unchanged at both T3 and T5 for PD and GAD
development.
Aim 3 Results: Anxiety as a Moderator of the Relationship Between Cannabis Use
Trajectories and Decision-Making.
At T5, there was no association found between cannabis use trajectory predicting
decision making (p > .05). However, there was a significant main effect of anxiety (β = .30, p =.035) on DM indicating that less anxiety was associated with better (i.e., less
risky) DM. Next, to determine if the association between cannabis trajectory membership
and DM varied by anxiety, we included an anxiety by cannabis group interaction term
and found a significant interaction (β = .237, p = .032), see Figure 10. To explore the
interaction, results from follow up testing revealed that anxiety moderates the relationship
between cannabis group trajectory and decision-making among adolescents only in the
minimal trajectory (β = -.185, p =.042), but not among those within the escalating or
chronic trajectories (p > .05). These findings suggest that anxiety levels impact DM
performance to a greater extent among participants with less frequent cannabis use than
among those with heavier use, see Table 8. Additionally, these results suggest that greater
anxiety among minimal users is associated with less risky decision-making. However, it
appears that that levels of anxiety do not influence the relationship between cannabis use
trajectories and risk-taking among those who escalate in use or are chronic users.
We used the same procedure described in previous aims to control for the
potential influence of depression on the associations between anxiety, cannabis group,
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and DM. These analyses revealed that the main effect of anxiety on DM dissipated (p
=.463), yet the interaction term of anxiety*cannabis group remained (β = .216, p =.039).
Furthermore, the main effect of depression on DM was marginally significant across all
cannabis groups (β = -.119, p = .057), suggesting that DM may be better (i.e., less risky)
at higher levels of depression for teens within all cannabis trajectory groups. These
findings suggest that depression may influence the association between anxiety and
cannabis trajectory on DM. To further explore support for a cross-over interaction, such
that the effect of anxiety on the association between cannabis group and DM depends on
the level of depression between groups, we conducted the same set of models with the
addition of an anxiety*depression interaction term. A significant interaction of
anxiety*depression term was found (β = -.15, p =.050). However, this finding was
revealed only for the escalating trajectory, and suggests that both depression and anxiety
interact and is related to poorer DM among users who increase their cannabis use rather
than those with minimal or steady chronic use.
CHAPTER V.
DISCUSSION
This set of studies examined associations between anxiety and cannabis use
trajectories with a sample of adolescents at risk for escalation in cannabis use. Findings
revealed that distinct patterns of adolescent cannabis use were associated with different
anxiety-related outcomes.
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Aim 1
Results from our Aim 1 analyses found that, on average, anxiety decreased over
the course of the two-year study period. We identified three main trajectories of cannabis
use in our sample: minimal use (i.e., consistently low levels throughout adolescence),
chronic use (i.e., consistently elevated levels throughout adolescence), and escalating use
(i.e., significantly accelerating use throughout adolescence). When examining
associations between cannabis use trajectory and changes in anxiety, results revealed that
adolescents in the escalating trajectory of cannabis use showed greater change in anxiety
symptoms over two years when compared to minimal and chronic users. Specifically,
adolescents in the escalating trajectory showed lesser decreases in anxiety over time
when compared to those in the minimal use trajectory. This suggests that increasing and
frequent cannabis use during adolescence may not an effective strategy for managing
anxiety and potentially leads to higher levels of anxiety relative to peers with different
patterns of use.
These results may be accounted for, at least in part, by several factors. First, the
expression of endocannabinoid CB1 receptors across the brain follows an age-dependent
downregulation (i.e., decreases in receptor numbers) which is associated with neural
structure development (Heng, Beverley, Steiner, Tseng, 2011). During adolescence, the
largest changes in CB1 expression occurs first in limbic regions and the prefrontal cortex
(Ellgren et al., 2008; Heng et al., 2011), regions of the brain which are associated with
emotion, anxiety, and decision-making. In addition to the natural course of cannabinoid
receptor reduction, prior work has found that short- and long-term use of cannabis during
adolescence contributes to neurochemical changes and subsequent deviations in
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cannabinoid receptor densities, most notably among CB1 receptors (Dalton &
Zavitsanou, 2010). Since, structures of the brain and the endocannabinoid system are
undergoing developmental changes in adolescence, it is possible that since THC binds to
CB1 receptors, neurocircuits may be affected and contribute to psychological symptoms
(Bossong & Niesink, 2010).
In addition to alterations in receptor densities, adolescent cannabis use has been
associated with desensitization of CB1 receptors, which is a reduction in receptormediated G-protein-coupled activity (Burston, Wiley, Craig, Selley, & Sim-Selley,
2010). Attenuation of receptor G-protein activity in neural receptors are associated with
variations in the regulation of physiological processes and neurotransmission (Howlett et
al., 2004). Within our study, we accounted for age by utilizing an accelerated cohort
design to generate our cannabis trajectories, and thus accounted for variance associated
with age as part of our models. However, different neural effects may have occurred
between cannabis groups, especially among users in the chronic and escalating
trajectories. That is, heavier patterns of use may have impacted the downregulation of
CB1 receptors, differently between groups, leading to differences in CB1 expression.
These possible differences in receptor expression subsequently may have influenced
growth in psychopathology and anxiety levels.
Another plausible explanation is that adolescents within our sample were selfmedicating with cannabis, consistent with the idea that increased substance use is a result
of maladaptively coping with emotional difficulties (Bolton, Robinson & Sareen, 2009;
Khantzian, 1997; Turner, Mota, Bolton, & Sareen, 2018). As we highlighted earlier, prior
research has shown support for a dose-biphasic effect with amount of THC consumed;
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such that initial low levels are often associated with anxiolytic effects, whereas chronic
and heavy use is associated with increased anxiogenic symptoms (Rey et al., 2012).
Considering that the anxiety effects we observed are associated with amount of cannabis
consumed, this may explain why participants within the escalating trajectory are showing
the greatest change in anxiety symptomology during the study period. Further,
participants within the escalating trajectory are showing a slower decrease in anxiety
when compared to other groups. Interestingly, we did not find significant differences
between chronic and minimal patterns of cannabis use on changes in anxiety symptoms.
We attribute these findings, in part, to additional factors within the biopsychosocial
framework of addiction. For example, adolescents who engage in initially high levels of
cannabis use and maintain this pattern overtime are not changing their use on the basis of
psychological or somatic symptoms of anxiety that may develop over time, indicating
they may have more appropriate anxiety-regulating strategies. However, more chronic
levels of early use may be influenced by genetic susceptibilities to addiction. Whereas,
escalating users may initiate use first following more social and psychological pressures,
and change their use over time to adapt with poor social relations and emotional
dysregulation.
Aim 2
To determine if distinct cannabis use trajectories were associated with
development of PD or GAD across the study period several models were conducted and
evaluated. Our findings revealed that adolescents among all cannabis use trajectories did
not differ in their development of PD during the course of the study (i.e., T3 or T5).
However, development of GAD at T3 was significantly associated with cannabis use
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group but not at T5. These results are somewhat surprising since we hypothesized that
increased cannabis use would be associated with more clinically elevated levels of
anxiety. Our hypothesis was guided by prior research in both rodent and human samples
that have indicated that the desensitization of CB1 receptors in limbic regions by
cannabis use is related to significantly elevated levels of anxiety (Hirvonen et al., 2012;
O’shea et al., 2004). Remarkably, our Aim 1 findings are consistent to these results, in
which we found escalating users to have slower decreases in anxiety, translating to
potentially higher levels of anxiety symptoms over time when compared to minimal
users. It may be that the teens in the minimal trajectory, who have clinically elevated
symptoms of anxiety, have other contributing factors that may better account for their
anxiety than solely cannabis use. This is of relevance since our follow-up findings found
interactive effects with cannabis group and sex on anxiety disorder development. Within
our sample, females were more likely to develop PD or GAD when compared to males
and is in agreement with prior research that has found anxiety to be more common among
females than males (Altemus, 2006).
Furthermore, developmental considerations between participants in each
trajectory may have contributed to our Aim 2 findings, in which participants in the
minimal group had greater odds of developing GAD than adolescents in the escalating
trajectory. Although we recruited a sample with comparable demographics and substance
use histories, it is possible that a subset of individuals may have skewed anxiety
outcomes differently across our three cannabis use trajectories due to unknown variables
not assessed.
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Additionally, as previously highlighted, anxiety follows a natural waxing and
waning pattern across adolescence. Prior research has found differences between the rate
of growth and reduction of PD and GAD symptom throughout the adolescent
developmental period, such that PD symptoms decrease in early to middle adolescence
compared with increases in GAD symptomology (Hale III et al., 2008). Correspondingly,
adolescent depressive symptoms are associated with future onset of GAD development
(Fergusson & Woodward, 2002; Moffit et al., 2007), and evaluation of depression onset
or evaluating GAD across a larger time-frame may have provided alternative outcomes.
In addition, several other factors are considered that may have contributed to our results.
When examining mean group differences of PD and GAD symptoms at T1, a significant
difference in GAD symptoms was observed, specifically greater GAD symptoms were
present among participants in the minimal trajectory when compared to those in the
escalating trajectory. Although these symptoms were not of clinical anxiety severity at T1
yet, it does support the possibility that those within the minimal trajectory joined our
study as more anxious individuals and which could have influenced anxiety growth to
clinically elevated levels. Furthermore, symptoms of worries about the future, health, and
illness, are notable symptoms of GAD (Newman, Llera, Erickson, Przeorski, &
Castonguay, 2013). Potential lack of worries associated with the health risks of smoking
could have served as a protective factor for more chronic and increasing levels of
cannabis use (Wells & Carter, 1999) among our participants. Alternatively, within the
early stages of use cannabis may be adaptive for managing acute physiological symptoms
of anxiety (as evidenced by our lack of PD development differences between cannabis
groups) but determining whether these results are evident across larger windows of time
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or are permanent warrants further examination. Thus, it appears the relationship between
cannabis use and anxiety disorder development share a bi-directional association with
one another yet identifying causal factors for poorer clinical outcomes remains
challenging.
Aim 3
Upon examining whether anxiety moderated the relationship between cannabis
use trajectories and risky DM, our results did not find evidence for a main effect of
cannabis pattern on DM. However, our results revealed a main effect for anxiety, as well
as a significant interaction between patterns of cannabis use and anxiety, indicating that
cannabis use patterns are associated with DM differently at various levels of anxiety. Our
initial findings suggest that minimal users with lower levels of anxiety had better DM
(i.e., less risk-taking) than those with higher levels of anxiety. These findings lend
support to prior evidence that have found increased anxiety is associated with risk averse
behaviors (Lorian & Grisham, 2011; Maner & Schmidt, 2006). Yet, it is interesting to
note that this established association is not observed (i.e., disrupted) at escalating and
more chronic levels of cannabis use. One potential hypothesis for our lack of risk
avoidance with higher levels of anxiety in escalating and chronic users may be related to
changes in brain executive functioning and emotional processing brain regions. As
previously discussed, THC binds to receptors in these areas of the brain (e.g., prefrontal
cortex, limbic area), and heavy prolonged use may disrupt neural pathways and signaling
that alter the association between anxiety and DM, ultimately resulting in a propensity for
making risky decisions, regardless of anxiety. However, we did not find a main effect for
cannabis trajectory on DM.
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Interestingly, however, these associations between anxiety, cannabis use patterns,
and DM appear to be influenced by comorbid depression. Exploratory, follow-up
analyses indicated that increased levels of depression interacted with anxiety to influence
greater risk-taking among adolescents who “escalate” in use. Thus, it appears that
associations between increasing cannabis use and anxiety vary as a function of depression
among adolescents who increase their use over time. Although longitudinal research
suggests that anxiety typically develops before depression in most cases (Feng, Shaw, &
Silk, 2008), and is more common than depression (Axelson & Birmaher, 2001), it
appears risky DM may be influenced by interactive effects of anxiety, depression, and
cannabis use.
Furthermore, although sex had significant associations with anxiety, cannabis
group, and DM performance, the stability of this relationship fluctuated as a result of
accounting for depression. That is, the main effect for sex between group comparisons
became insignificant when depression was added into our models. Nonetheless, females’
DM performance was more adversely affected by anxiety and depression across cannabis
groups, suggesting that cannabis and internalizing pathology interact differently for males
and females. These sex effects map onto prior research that has indicated internalizing
pathology is more common among adolescent females than males (Soloman & Herman,
2009), and can lead to poorer neurocognitive outcomes (Eysenck, Derakshan, Santos, &
Calvo, 2007). Accordingly, although we did not find evidence to support prior claims that
cannabis use affects DM (Bolla, Eldreth, Matochik, & Cadet, 2004), our results replicate
studies who have not found effects of cannabis on DM (De Bellis et al., 2013; Eldreth,
Matochek, Cadet, & Bolla, 2004; Gonzalez et al., 2012; Lyons et al., 2004), including a
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preliminary study from our lab utilizing the same sample with data from baseline through
T3 (Duperrouzel et al., 2019).
Our results also complement the extant literature and indicate that female users
may be at a greater risk than males for adverse mental health consequences and cognitive
outcomes as a result of adolescent cannabis use, regardless of cannabis use trajectory.
Strengths of Present Study.
There are several strengths of the present study. First, the study followed a
relatively large sample of youths at risk for cannabis use escalation with an impressive
retention record across two years. Across the study windows, multiple data points
regarding demographic, social, emotional, substance use, and cognitive functioning were
captured and allowed for the opportunity to evaluate change across these domains.
Additionally, previously identified patterns of cannabis use were replicated within our
sample and included steady low levels, chronic high levels, and an increasing pattern of
cannabis use. Overall, the wealth of data collected across five time-points allowed for
further examination of associations between patterns of cannabis use and adverse anxiety
outcomes than currently available in the literature. Although one of the most frequent
reasons cited for cannabis use among teens is for the reduction of stress, teasing apart
anxiety by disorder sub-types further enhances our understanding on the complex
relationships between cannabis use and anxiety. Our study was also able to identify
differences in the severity of anxiety sub-types and identifying which patterns of use are
more susceptible to developing clinical levels of GAD and PD over time. Interestingly,
patterns of cannabis use appear to affect differences in anxiety over time. Additionally,
our results suggest that levels of anxiety can moderate relationships between cannabis use
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and executive functioning (e.g., decision making). Thus, from our findings, it appears that
cannabis use and anxiety have a bi-directional influence that impacts growth within each
domain over time throughout mid to late adolescence.
Within our follow up analyses, we also identified several interesting avenues for
future research which included the identification of sex differences in these associations,
as well as the influence of comorbid depression. Through these findings, we have been
able to further identify individuals who may be most at risk for poorer anxiety outcomes,
with our results suggesting females and individuals with comorbid depressive symptoms
to be most affected by higher levels of cannabis use. Interestingly, our study was also
able to shed light on the potential neurocognitive effects of anxiety and cannabis use on
risky DM. Although adolescence in general is often characterized as a period of
heightened risk-taking (Casey, Getz, & Galavan, 2008), factors that contribute to even
riskier DM have the potential to lead to extreme consequences such as teenage
pregnancy, school underachievement and dropout, other substance use, and even death
(Chakravarthy, Shah, & Lotfipour, 2013). Our findings suggest that cannabis use patterns
do not predict decision making outcomes among youth in the early stages of use.
However, results from our model looking at bidirectional influences of cannabis use
trajectory and anxiety on decision-making suggest the anxiety moderates the relationship
between cannabis and risk-taking. More specifically, our findings identified that a
minimal cannabis use pattern and greater levels of anxiety can interact to make DM better
(i.e., less risky). Interestingly, we did not find statistical evidence that among teens with
higher levels of anxiety, heavier patterns (i.e., chronic and escalating trajctories) were
associated with risker DM. However, when representing the anxiety by cannabis group
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interaction data in a graph format, it appears that the relationships between heavier
patterns of CU and DM are affected differently at various levels of anxiety, when
compared to teens with minimal cannabis use. Thus, continuing to identify factors that
contribute to more negative outcomes can help aid in targeted prevention and intervention
efforts. It will be important to continue to examine these associations between levels of
anxiety and patterns of CU on DM over time to determine if these associations fluctuate,
dissipate, or are stable.
Furthermore, our results partially support the self-medication hypothesis
regarding somatic symptoms of anxiety (as indicated by Aim 1 findings), which posits
that substance use is initiated/maintained in order to relieve uncomfortable affective
states, such as anxiety or depression (Khantzian, 1997). Adopting a self-medicating
motive for cannabis use as a youth can help maintain maladaptive coping mechanisms,
and ultimately lead an individual to the development of substance use disorders and other
addictions. While substances like cannabis may be perceived as less harmful when
compared to other drug classes such as opiates and amphetamines (Miech et al., 2019),
using a substance in an effort to regulate emotional states through drug related “highs”
and “euphoria” rather than addressing maladaptive stress, anxiety, and depressive
contributes to negative reinforcement cycles (Koob & Kreek, 2007; Sinha, 2008). Lastly,
these findings extend and support prior findings from our lab, in which higher levels of
cannabis use appear to be most associated with more negative psychological
consequences. Although we did find evidence for greater probability of the minimal
trajectory developing GAD when compared to chronic and escalating users, we suspect
that these results may be transient and not indicative of long-term negative outcomes of
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low use, or may be better accounted for by our participant sampling methods.
Nonetheless, we suspect that the lack of evidence for more adverse anxiety outcomes
among the escalating and chronic trajectories may also be heavily influenced by the
relatively minimal levels of reported anxiety within our study.
Limitations.
These findings should be considered in light of several limitations. First, our
sample consisted of adolescents in the early stages of cannabis use in an attempt to
capture different growth patterns of use over a two-year period. However, previous
studies examining cannabis use trajectories across different developmental stages have
found that patterns of use vary depending on the age of participants captured. For
example, a study examining a large community sample of high-school students (n=1,205)
found five distinct cannabis patterns emerge across their sample, including our
aforementioned trajectories, as well as, decreasers and experimental users (Windle &
Wiesner, 2004). On the other hand, a large regional study, recruited 5,833 participants
from California and Oregon with ages ranging between 13-23 and found four distinct
patterns of cannabis use over a 10-year period (Ellickson et al., 2004). Since the present
study recruited a robust sample from the greater Miami area, when comparing the sample
size to other studies examining cannabis use trajectories, our findings remain somewhat
disparate. With an even larger study sample, we potentially could have identified
different cannabis use trajectories than the ones we captured. Additionally, within our
study, we were interested in utilizing LCGA to identify patterns of use within our sample
specifically (i.e., teens in early stages of cannabis use), and not necessarily indicative of
cannabis patterns found in the population at large. Although we utilized an accelerated
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cohort design to capture a larger range of ages within our sample, the estimates for these
simulated ages were influenced by the participant characteristics of our sample (e.g.,
majority exposed to alcohol, nicotine, or cannabis use, even if only minimally). Perhaps
with a more diverse sample, we would have identified different trajectories, with possibly
initiation of heavy use at different ages. Furthermore, if we had studied our participants
for longer, and even across different developmental periods, such as young adulthood, we
may have been able to identify trajectories like adolescent-limited trajectories or even
“decreasers,” that is individuals who decrease use over time. Thus, it is possible that our
results depict only a small snapshot of the associations between adolescent cannabis use
and anxiety, and that a larger more diverse sample of adolescents may have had different
class trajectories and anxiety outcomes.
Other study limitations are related to the characteristics of our sample and parent
study design. For instance, approximately 90% of participants in our sample were of
Hispanic/Latino/a ethnicity. According to the MTFS, Hispanic adolescents report earlier
initiation of cannabis use and greater use during adolescence when compared to
Caucasian adolescents (Johnston et al., 2018; Miech et al., 2015). Hence, the findings we
report here may not generalize to larger more diverse samples that include individuals
from a more varied range of ethnic backgrounds. Additionally, parent study exclusion
criteria included clinically elevated levels of psychopathology in several areas at the time
of screening (e.g. mood disorders, thought disorders, etc). Nevertheless, 7% of our
participants did meet criteria for internalizing disorders at baseline, and an additional 8%
developed it over the course of the study. Because our main outcome variables were
related to more elevated levels of anxiety, our results should be interpreted within the
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framework of a typically developing healthy sample. Associations between cannabis use,
anxiety, and decision-making may vary among individuals with more severe and
clinically elevated levels of anxiety.
It is also possible that the tools employed to assess anxiety and mental health may
not have been the optimal. For instance, the C-DISC used criteria from the DSM, 4th
edition revised. However, when the DSM-5 was published in May 2013, criteria for PD
changed. Of the main noteworthy changes, PD and agoraphobia (i.e., the fear of
situations or places that cause panic), were separated, and changes were made to panic
attack types. Additionally, PD diagnosis would not occur if it is better accounted for by
another disorder such as SAD (Asmundson, Taylor, & Smits, 2014). Since, our study did
not capture SAD symptoms, it is difficult to determine whether panic attacks were
associated with SAD or true PD. Furthermore, because we did not examine SAD,
replication of prior established effects with CU was restricted with our sample.
Moreover, our findings reported on the associations between cannabis trajectories
and changes in PD and GAD symptoms, whereas the extant literature has focused more
heavily on associations between changes in adolescent cannabis use and symptom
changes in SAD. As SAD is the most highly prevalent anxiety disorder among cannabis
users, and a proposed risk factor for cannabis dependence (Buckner et al., 2008), it would
have been informative to replicate these findings in our sample. Additionally, because our
follow-up analyses indicated sex differences between associations with anxiety and
cannabis trajectory group, most notably among females, it is contrasting to sex
differences associated with SAD and cannabis use; in which males are more adversely
affected than females (Buckner, Zvolensky, & Schmidt, 2012). Despite the reliability and
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validity of the measures used to assess psychopathology in our sample of adolescents,
future work would benefit from including multiple measures of anxiety that capture more
common adolescent anxiety disorders to replicate and extend previous findings. Other
measures that would be helpful in the assessment of adolescent anxiety with cannabis use
would be to account for level of neuroticism with sample participants.
Finally, previous work suggests that the association between SAD and adolescent
cannabis use is related to peer relations and social support (Nelemans et al., 2016).
Earlier research indicates that adolescents with greater peer involvement may have more
opportunities to participate in experimentation and cannabis abuse. Whereas, teens with
SAD may be more socially isolated. Since adolescent cannabis use generally occurs with
peers, those not participating in social engagements with peers may be limited in their
opportunities to use cannabis routinely (Nelemans et al., 2016). It is possible that our
results may also have been influenced by social factors we did not explore. Consequently,
more work is needed to determine how and what social mechanisms contribute to adverse
mental health and cognitive outcomes among cannabis using youth.
Conclusions and Future Directions.
In conclusion, our findings contribute to the understanding of the complex
associations between adolescent cannabis use and anxiety. It appears that escalating
pattern of cannabis use is worse for current anxiety symptoms (i.e., past week) among
teens. Our analyses specifically found that increasing use across the study period was
associated with higher levels of past week anxiety symptoms at two year follow up than
when compared to minimal and chronic patterns of cannabis use. Alternatively, it appears
that adolescents with the lowest levels of cannabis use have the greatest risk of
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developing an anxiety disorder. We highlighted several hypotheses as to why this may
occur, and include contributing factors of SAD not examined here, heightened initial
levels of anxiety, and other external factors not evaluated (e.g., neuroticism). Lastly, we
found that various levels of anxiety interacts with different patterns of cannabis use to
influence DM differently, and that this association also varies with depression and sex.
These findings are of great importance because it helps identify adolescents who may
potentially be at risk for more adverse neurocognitive outcomes in the future. Although
further work is needed to solidify our understanding of these relationships, our results
indicate that adolescent cannabis use is associated with changes in anxiety, anxiety
disorder development, and interacts with anxiety to influence risky decision-making. It is
also evident that distinctive patterns of cannabis use affect males and females differently
and more work is needed to help identify mechanisms that contribute to these disparate
outcomes. Furthermore, comorbidity with depressive symptoms appears to influence
associations between anxiety and cannabis use, and more work is needed to identify how
differences in affective and mood symptoms interact.
The results presented here help further inform clinical decision making for mental
health professionals treating adolescents with anxiety disorder symptoms, in regard to
anxiety course with comorbid patterns of cannabis use. Furthermore, prevention of
clinically elevated anxiety symptoms during early adolescence may have important
secondary effects on preventing future cannabis use and adverse DM, which may lead to
negative outcomes such as teen pregnancy, school dropout, and other substance use.
Mental health professionals aimed at reducing levels of anxiety through methods focused
on acquiring healthy coping mechanisms for stress and worries, such as through cognitive
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behavioral therapy (CBT) strategies may subsequently buffer potential cannabis use for
self-medicating mechanisms. Additionally, mental health providers should assess
comorbid depression among teens who use cannabis and have anxiety, especially among
females, as they may engage in more riskier decision-making. Thus, it is important for
prevention and intervention efforts to not only be aware of psychopathological and
substance use factors contributing to poorer outcomes, but also be aware that other social
factors, such as peer involvement, psychological variables like neuroticism, and other
biological influences (e.g., genes) may be contributing to these outcomes. Earlier we
presented the biopsychosocial model in an attempt to guide our aims and hypotheses in
relation to associations between anxiety and cannabis use. Greater targeted prevention for
ameliorating anxiety among adolescents should take a systems perspective in an attempt
to identify social, psychological, and biological factors contributing to negative outcomes
and maladaptive coping mechanisms among adolescents.
Correspondingly, the National Institute of Health’s partnership titled,
Collaborative Research on Addiction (CRAN), promotes an interdisciplinary framework
in which numerous national agencies can receive funding to aid and further our
understanding of addiction science. Through a systems approach of evaluation, addiction
research will be enriched through collaborations across genetic, epigenetic, molecular,
neurobiological, behavioral, and social science disciplines.
Currently, there are several large, longitudinal government-funded projects that
are in progress and seek to identify factors that contribute to substance abuse. The
Adolescent Brain and Cognitive Development (ABCD) study, is a national landmark
project that began in September 2015 and recruited over 11,000 children aged 9 to 10.
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The project is comprised of a consortium of 21 research sites across the United States to
recruit a nationally represented sample of children. Participants will complete numerous
assessments each year for ten years, in an effort to collect data on social, emotional,
biological, cognitive, and neural domains throughout development into young adulthood.
Since adolescence is characterized as a period of substance use initiation and heightened
developmental changes, understanding factors that contribute to harmful substance use
trajectories is critical. Data gathered from participants during the pre-adolescent,
adolescent, and post-adolescent years will hopefully allow for precursors of substance
abuse to be identified and aid in prevention and intervention efforts. Other current CRAN
funded projects include projects examining adolescent alcohol use, drug use prevention
among HIV samples, cocaine addiction, and methamphetamine reward and relapse
mechanisms. Furthermore, at the time of this dissertation (September 2019), 25 CRAN
related research projects had received federal funding, with an additional two pending
revision approval. Findings from these studies will further promote our understanding on
factors that contribute to more adverse outcomes from substance use.
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APPENDICES

Table 1: Descriptive Statistics for Study Sample at Baseline

Age
Years of Education
Years of Education (Mother)
Years of Education (Father)
WRAT-4 Reading Standard Score
Ethnicity/race (%)
Hispanic/Latino
Caucasian
African-American
Other
Female (%)
Substance Use
Amount of Lifetime Nicotine (cigarettes; MD, IQR)
Frequency of Lifetime Nicotine (cigarettes; MD, IQR)
Amount of Lifetime Alcohol (1 serving; MD, IQR)
Frequency of Lifetime Alcohol (1 serving; MD, IQR)
Amount of Lifetime Cannabis (g; MD, IQR)
Frequency of Lifetime Cannabis (days, MD, IQR)
Ever Used Cannabis (%)
Used Cannabis in Past Month (%)
Used Cannabis in Past Six Months (%)
Used Cannabis in Past Year (%)
Ever Used Alcohol (%)
Ever Used Nicotine (%)

Escalating Trajectory
(n = 78)
15.88 (.63)B

Chronic Trajectory
(n = 61)
15.65 (.65)A

108.52 (13.9)

14.05 (2.75)
13.36 (2.92)
108.68 (14.73)

14.00 (2.49)
13.36 (3.00)
106.93 (14.53)

91%
4%
4%
1%
57% A

82%
7%
10%
1%
23%B

96%
2%
2%
0%
28%B

0 (0, .25)A

0 (0, 5.75)A
0 (0, 6)A
18 (3.38, 65.75)AB
7.5 (2, 21.75)AB
61.34 (17.28, 174.63)B
82.5 (36.5, 256)B
100%B
85%B
96%B
100%B
94%B
49%B

2 (0, 29)B
2 (0, 24.5)B
20 (7.75, 110.5)B
10 (2, 40)B
172.95 (76, 376)C
309 (180, 597)C
97%B
92%C
95%C
97%C
92%B
70%C

Minimal Trajectory
(n = 262)
15.64 (.70)A
14.34 (2.42)
13.98 (2.86)

0 (0, 1)A

5 (1, 39)A
3 (1, 16)A

1.88 (0, 15.98)A
6 (0, 32)A
68%A
35%A
60%A
65%A
77%A
32%A

Note: Abbreviations: WRAT-4, Wide Range Achievement Test; DASS-21, SD, standard deviation; Md, median; IQR,
interquartile range. Superscript letters indicate significant mean differences between groups (p < .05).
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Table 2: Participant Characteristics for Aim 1

T5 Lifetime Frequency of Cannabis Use
(g; MD, IQR)
T5 Lifetime Amount of Cannabis Use
(g; MD, IQR)
T5 Lifetime Frequency of Alcohol Use
(1 serving; MD, IQR)
T5 Lifetime Amount of Alcohol Use
(1 serving; MD, IQR)
T5 Lifetime Frequency of Nicotine
(cigarettes; MD, IQR)
T5 Lifetime Amount of Nicotine
(cigarettes; MD, IQR)
Mental Health, Mean (SD)
DASS-21 Anxiety Z-Score at T1
DASS-21 Anxiety Z-Score at T5
DASS-21 Depression Z-Score at T1
DASS-21 Depression Z-Score at T5
DASS-21 Stress Z-Score at T1
DASS-21 Stress Z-Score at T5

Minimal Trajectory
(n = 262)
15 (0, 70.5)A

Escalating Trajectory
(n = 78)
218 (122.75,418)B

Chronic Trajectory
(n = 61)
529 (414.5, 804)C

4.9 (0, 32.83)A

171.86 (71.69, 363.89)B

479 (249.92, 752.50)C

17 (6, 54.5)A

35 (14.25, 108.25)B

43 (17, 125.5)B

48.16 (12.13, 182.83)A

157 (38, 395.2)B

156 (56, 558.5)C

4 (0, 20)A

104.5 (45, 176.25)B

186 (151, 258.5)C

2 (0, 20)A

86.26 (37.36, 224.69)AB

222.75 (115.5,
409.73)B

-.30 (.90)

-.34 (.86)
.16 (1.51)B
.34 (.86)
-.17 (.80)
-.54 (.80)
-.42 (1.13)

-.31 (.70)
.04 (1.07)B
-.31 (.70)
-.23 (.96)
-.48 (.76)
-57 (.92)

-.33 (1.06)A

-.30 (.90)
-.42 (.90)
-.44 (.90)
-.62 (.84)

Note: Abbreviations: Depression, Anxiety, and Stress Scale, Short Version (DASS-21); Md, median; IQR, interquartile range.
Superscript letters indicate significant mean differences between groups (p < .05).
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Table 3: Participant Characteristics for Aim 2
Minimal Trajectory
(n = 262)
15 (0, 70.5)A
4.9 (0, 32.83)A

Escalating Trajectory
(n = 78)
218 (122.75,418)B
171.86 (71.69, 363.89)B
451 (280, 608)B
353 (192.83, 605.9)B

Chronic Trajectory
(n = 61)
529 (414.5, 804)C
479 (249.92, 752.50)C
818 (644, 1032)C
806.41 (474.57, 1275.78)C
20 (6.5, 81)B

T3 Lifetime Frequency of Cannabis Use (g, MD, IQR)
T3 Lifetime Amount of Cannabis Use (g, MD, IQR)
23 (0, 108.5)A
T5 Lifetime Frequency of Cannabis Use (g, MD, IQR)
7.65 (0, 61.9)A
T5 Lifetime Amount of Cannabis Use (g, MD, IQR)
T3 Lifetime Frequency of Alcohol Use
10 (2, 32)A
19.5 (6, 52)A
(1 serving; MD, IQR)
64 (24, 290.5)B
T3 Lifetime Amount of Alcohol Use
19 (3, 90.33)A
59.5 (17, 179.5)A
(1 serving; MD, IQR)
17 (6, 54.5)A
35 (14.25, 108.25)B
43 (17, 125.5)B
T5 Lifetime Frequency of Alcohol Use
(1 serving; MD, IQR)
48.16 (12.13, 182.83)A
157 (38, 395.2)B
156 (56, 558.5)C
T5 Lifetime Amount of Alcohol Use
(1 serving; MD, IQR)
1 (0. 13.5)B
15 (1, 56)C
T3 Lifetime Frequency of Nicotine (cigarettes; MD, IQR)
0 (0, 3.5)A
0
(.59,
33.5)
AB
22.75
(.25, 122)B
T3 Lifetime Amount of Nicotine (cigarettes; MD, IQR)
0 (0, 3)A
4 (0, 20)A
104.5 (45, 176.25)B
186 (151, 258.5)C
T5 Lifetime Frequency of Nicotine (cigarettes; MD, IQR)
2 (0, 20)A
86.26 (37.36, 224.69)AB
222.75 (115.5, 409.73)B
T5 Lifetime Amount of Nicotine (cigarettes; MD, IQR)
Mental Health, Mean (SD)
-.20 (1.20)
.14 (1.37)
.15 (1.15)
DASS-21 Anxiety Z-Score at T3
-.28
(.99)
-.37
(.79)
-.22 (.98)
DASS-21 Depression Z-Score at T3
-.51
(.95)
-.49
(.87)
-.50 (.90)
DASS-21 Stress Z-Score at T3
.49 (.93)B
.59 (1.10)AB
C-DISC GAD Symptoms at T3
.50 (.92)A
2.38 (2.32)
1.88 (1.81)
C-DISC PD Symptoms at T3
2.81 (2.31)
.39
(.92)
.47 (.82)
C-DISC GAD Symptoms T5
.46 (.91)
2.17 (2.07)
1.85 (1.78)
C-DISC PD Symptoms at T5
2.18 (2.12)
Note: Abbreviations: DASS-21, Depression, Anxiety, Stress, Scale, 21-item version; Computer Diagnostic Interview Schedule for
Children, Fourth Edition (C-DISC); Md, median; IQR, interquartile range. Superscript letters indicate significant mean differences
between groups (p < .05).
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Table 4: Participant Characteristics for Aim 3

Substance Use, MD (IQR)
T5 Lifetime Frequency of Cannabis Use (grams)
T5 Lifetime Amount of Cannabis Use (grams)
T5 Lifetime Frequency of Alcohol Use
(days)
T5 Lifetime Amount of Alcohol Use
(1 serving)
T5 Lifetime Frequency of Nicotine (days)
T5 Lifetime Amount of Nicotine (cigarettes)
Mental Health, Mean (SD)
DASS-21 Anxiety Z-Score at T5
DASS-21 Depression Z-Score at T5
DASS-21 Stress Z-Score at T5
Decision Making Measures, Mean (SD)
IGT Net Total Reverse Scored
Cups Gain Total
Cups Loss Total
GDT Total Risky Trials

Minimal Trajectory
(n = 262)

Escalating Trajectory
(n = 78)

Chronic Trajectory
(n = 61)

15 (0, 70.5)A
4.9 (0, 32.83)A
17 (6, 54.5)A

218 (122.75,418)B
171.86 (71.69, 363.89)B
35 (14.25, 108.25)B

529 (414.5, 804)C
479 (249.92, 752.50)C
43 (17, 125.5)B

48.16 (12.13, 182.83)A

157 (38, 395.2)B

156 (56, 558.5)C

4 (0, 20)A
2 (0, 20)A

104.5 (45, 176.25)B
86.26 (37.36, 224.69)AB

186 (151, 258.5)C
222.75 (115.5,
409.73)B

-.33 (1.06)A

-.42 (.90)
-.62 (.84)
-11.83 (28.99)

17.34 (5.59)
17.78 (6.09)
5.24 (4.66)

.
16 (1.51)B
-.17 (.80)
-.42 (1.13)

.04 (1.07)B
-.23 (.96)
-57 (.92)

-6.68 (27.96)
16.54 (5.06)
16.74 (6.37)
5.68 (4.98)

-6.68 (27.50)
17.67 (5.49)
15.77 (6.45)
6.23 (5.01)

Note: Abbreviations: DASS-21, Depression, Anxiety, Stress, Scale, 21-item version; Iowa Gabling Test; GDT, Game of Dice
Task; SD, standard deviation; Md, median; IQR, interquartile range. Neurocognitive performance was assessed at T5. Superscript
letters indicate significant mean differences between groups (p < .05).
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Table 5: Fit Information for Latent Class Growth Analyses of Cannabis Trajectories
BIC

Entropy

BLRT

2-Class

18700.77

.960

p = 0.00

3-Class

18465.28

.922

p = 0.00

4-Class

18368.17

.916

p = 0.00

Note. Abbreviations: BIC=Sample size adjusted Bayesian Information Criterion. BLRT = Bootstrapped Likelihood Ratio.
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Table 6: Results of cannabis use trajectory membership predicting changes in anxiety symptomology across two-years
Trajectory Class Membership Comparisons1
Minimal vs. Escalating CU

Minimal vs. Chronic CU

Chronic v. Escalating CU

DASS-21 Change

-.37 (.18) p = .03*

.11 (.15) p =.46

-.77 (.34) p =.04*

PD Symptoms Change

-.29 (.17) p =.09

.15 (.13) p = .28

-.14 (.25), p = .58

GAD Symptoms Change

-.17 (.13) p =.19

-.06 (.12) p =.62

.26 (.17) p =.12

Predictors

Note. Abbreviations: Cannabis Use (CU); Depression, Anxiety, and Stress Scale, Short Version (DASS-21); Panic Disorder (PD);
Generalized Anxiety Disorder (GAD). Linear regression statistics by comparison class presented with standardized estimates,
standard error, and p-value. 1First CU trajectory group listed for each comparison serves as the reference group. *p<.05; ***p<.001
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Table 7: Results of cannabis use trajectory membership predicting panic disorder and general anxiety disorder membership at 1year and two-year follow-up

Trajectory Class Membership Comparisons1
Chronic vs. Minimal CU

OR (95% CI)

Chronic vs. Escalating CU
OR (95% CI)

Minimal v. Escalating CU
OR (95%

Panic Disorder T3

1.11 (.11, 11.2)

.80 (.15, 4.27)

.39 (.10, 1.43)*

Panic Disorder T5

∞2

∞2

.63 (.16, 2.51)

Generalized Anxiety T3

∞2

∞2

1.31 (.31, 5.57)

Generalized Anxiety T5

∞2

∞2

.82 (.17, 2.40)

Predictors

Note. Abbreviations: Cannabis Use (CU). 1Odds ratios derived from logistic regression estimates in Mplus. ∞2 = not
applicable: odds ratio could not be calculated because one of the cells contained zero: participants in the chronic trajectory did not have
panic disorder at T5, or generalized anxiety disorder at T3 or T5. First CU trajectory group listed for each comparison serves as

the reference group. *p<.05; ***p<.001
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Table 8. Model parameter estimates of the interactive effects of anxiety and cannabis use trajectory membership with
decision-making at two-year follow-up
Standardized
Estimate

Unstandardized
Estimate (SE)

p-value

CU Group → Decision Making

-.04

.013

p = .497

Anxiety →Decision Making*

-30

.025

p = 035

GroupXAnxiety → Decision Making*

.24

.010

p = .041

Gender → Decision Making**

.19

.025

p < .001

FSIQ → Decision Making*

-.12

.11

P = .036

Alcohol → Decision Making*

.12

.000

p = .021

.022

p = .922

Paths
Decision Making Main Model

Nicotine → Decision Making
-.01
Note. Abbreviations: Cannabis Use (CU). *p<.05; ***p<.001.
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Figure 1: Proposed Biopsychosocial Model of Anxiety and Cannabis Use
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Figure 2: Reinforcement Model of Anxiety through Self-Medicating with Cannabis Use
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Figure 3: Assessment Timeline from Baseline to T5
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Figure 4: Trajectories of Adolescent Cannabis Use at Baseline – Three Classes
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Figure 5: Trajectories of Adolescent Cannabis Use at Baseline – Four Classes

Lifetime Cannabis Use Frequency (in days)

250

200

150

100

50

0
14.5

15

15.5

16

16.5

Participant Age

75

17

17.5

18

18.5

Figure 6: Changes in DASS-21 Anxiety Symptoms by Cannabis Use Trajectory from T1-T5
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Figure 7: Changes in PD Symptoms by Cannabis Use Trajectory from T1-T5
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Figure 8: Changes in GAD Symptoms by Cannabis Use Trajectory from T1-T5
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Figure 10: The Moderating Role of Anxiety on the Association Between Cannabis Use Trajectory and Decision-Making
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